Wacker Biotech acquires biologics firm, BioNet Ventures

Wacker Biotech acquires biologics firm, BioNet Ventures

11:26 AM, 13th November 2013
Wacker Biotech acquires biologics firm, BioNet Ventures

MUNICH/HALLE, GERMANY: Wacker Biotech GmbH, a subsidiary of Wacker Chemie AG, is acquiring a production site for bioengineered pharmaceutical proteins (biologics), including the associated business, from BioNet Ventures GmbH.

WACKER’s acquisition covers the assets of Scil Proteins Production at the SCIL site in Halle, eastern Germany, including the patent portfolio. WACKER will be continuing Scil Proteins Production’s existing customer partnerships. The Munich-based chemical group will also retain the SCIL staff. The transaction is expected to close early next year.

“We see the acquisition as a crucial step towards extending our service to customers to cover the market-supply phase following approval of customer drugs more adequately,” said Dr Gerhard Schmid, President, WACKER BIOSOLUTIONS.

“Our partners’ various pharmaceutical projects, which we have proactively supported during preclinical and clinical development, are about to be launched on the market. Expanding our production capacities in this way comes at an ideal time for both ourselves and our customers. Additionally, SCIL’s refolding expertise complements our own technology platforms and extends the range of services that we offer as a leading contract manufacturer of biopharmaceutical proteins with microbial technologies,” explained Schmid.


© Worldofchemicals News



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Carbon dioxide, a renewable feedstock; says Cefic

BRUSSELS, BELGIUM: According to Cefic Innovation Head, Gernot Klotz, chemical industry use of carbon dioxide (CO2) as a renewable resource can support ...

Read more
Unipetrol to acquire Shell’s 16.3 pc stake in Ceska Rafinerska

PRAGUE, CZECH REPUBLIC: Unipetrol, Czech downstream oil group, has agreed to buy partner Royal Dutch Shell’s 16.3 per cent stake in Ceska Rafine ...

Read more
Novartis sells blood transfusion diagnostics unit to Grifols for $1.675 billion

BASEL, SWITZERLAND: Novartis announced a definitive agreement to divest its blood transfusion diagnostics unit to Grifols for $1.675 billion. This tra ...

Read more
KBR bags contract to study Fertial’s ammonia plants in Algeria

HOUSTON, US: KBR, a global engineering, construction and services company, has been awarded a contract by Fertial SpA to conduct a study that will imp ...

Read more
Eastman appoints new Senior Vice President, Chief Technology Officer

KINGSPORT, US: Eastman Chemical Company appointed Stephen G Crawford as Senior Vice President and Chief Technology Officer, effective from 1 January 2 ...

Read more
Engineered bacteria to synthesize drugs, biofuels

CAMBRIDGE, US: Kristala Jones Prather, Associate Professor, MIT designed new ways to engineer bacteria to synthesize useful chemical compounds such as ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X